Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
49 hedge funds and large institutions have $116M invested in Allena Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 5 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $90.8M → $116M (+$25.7M)
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$699K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$623K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$434K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$258K |
| 5 |
BlackRock
New York
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.21M |
| 2 |
Morgan Stanley
New York
|
-$314K |
| 3 |
JP Morgan Chase
New York
|
-$109K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$93K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$76.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citadel Advisors
Miami,
Florida
| – | -$60K | -10,970 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$30K | -5,488 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$6K | -1,049 | Closed |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | -163 | Closed |
|
ALNA Hedge Fund Activity: Q1 2019 in Review
49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q1 2019, worth a combined $116M — up 28% from $90.8M a quarter earlier.
Fund positioning in ALNA was balanced in Q1 2019: 5 funds opened new positions, 5 closed out, 12 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $699K. The largest seller was PFM Health Sciences, cutting an estimated $2.21M.
- 49 institutional investors held Allena Pharmaceuticals (ALNA) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $116M of Allena Pharmaceuticals stock for Q1 2019, up 28% quarter-over-quarter.
- 5 funds opened new Allena Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of 0 holders.
- The largest Allena Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $699K added.
- The largest Allena Pharmaceuticals seller in Q1 2019 was PFM Health Sciences, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2019.